LONDON (Alliance News) - ReNeuron Group PLC Friday said it will look at whether the UK government's plan to launch a scheme to encourage the take up of novel therapies could be applied to its own therapeutic candidates.
The scheme, called the Early Access to Medicines Scheme, is looking to enable faster access to medicines for patients with life threatening of seriously debilitating conditions which currently have no available treatments.
ReNeuron develops new stem cell therapies that target areas of medicine that are not significantly, or poorly, met by current treatments. It said it will explore the applicability of the new scheme on its own therapeutic candidates, as it may allow them to be offered to patients in the UK through the National Health Service at an earlier stage in the development cycle.
"We are seeing a clear push from governments and regulatory authorities in major territories around the globe to establish robust but much faster and more efficient routes to market for novel therapies in areas of unmet medical need," said Chief Executive Michael Hunt in a statement. "Given ReNeuron's focus in these areas, we see the business and the patients who may benefit from its treatments as prime beneficiaries of these global developments."
Shares in ReNeuron were trading down 4.2% at 3.26 pence Friday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)